Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy

Kidney International

Volumn 81, Issue 5, 2012, Pages 494-501

  Gross, Oliver ^a   Licht, Christoph ^b   Anders, Hans J ^c   Hoppe, Bernd ^d   Beck, Bodo ^d   Tönshoff, Burkhard ^e   Höcker, Britta ^e   Wygoda, Simone ^f   Ehrich, Jochen H H ^g   Pape, Lars ^g   Konrad, Martin ^h   Rascher, Wolfgang ⁱ   Dötsch, Jörg ^d   Müller Wiefel, Dirk E ^j   Hoyer, Peter ^k   Knebelmann, Bertrand ^l   Pirson, Yves ^m   Grunfeld, Jean Pierre ^l   Niaudet, Patrick ^l   Cochat, Pierre ⁿ   Heidet, Laurence ^l   Lebbah, Said ^l   Torra, Roser ^o   Friede, Tim ^a   Lange, Katharina ^a   Müller, Gerhard A ^a   Weber, Manfred ^p   more..

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f Klinikum St Georg   (Germany)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h UNIVERSITY HOSPITAL MÜNSTER   (Germany)

ⁱ UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^j UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^k UNIVERSITY HOSPITAL ESSEN   (Germany)

^l HÔPITAL NECKER ENFANTS MALADES   (France)

^m CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

ⁿ UNIVERSITÉ DE LYON   (France)

^o FUNDACIÓ PUIGVERT   (Spain)

^p UNIVERSITY OF WITTEN HERDECKE   (Germany)

more..

Author keywords

Alport syndrome; chronic kidney disease; fibrosis; nephroprotection; renal insufficiency

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; AGGRESSION; AGITATION; ALPORT SYNDROME; ANGIONEUROTIC EDEMA; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; COUGHING; DIALYSIS; DRUG FATALITY; DRUG WITHDRAWAL; ENZYME INHIBITION; FATIGUE; FEMALE; HEMATURIA; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MOUTH ULCER; PATIENT CODING; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; PROTEINURIA; RELATIVE; SIBLING; SIDE EFFECT; SLEEP DISORDER; THERAPY DELAY; TREATMENT RESPONSE;

EID: 84857109752     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.407     Document Type: Article

References (31)

1. Hostetter TH. Chronic kidney disease predicts cardiovascular disease. N Engl J Med 2004; 351: 1344-1346. (Pubitemid 39258430)
2. Ritz E, Bakris G, World Kidney Day Organising Committee. World Kidney Day: hypertension and chronic kidney disease. Lancet 2009; 373: 1157-1158.
3. Gross O, Netzer K-O, Lambrecht R et al. Meta-analysis of genotypephenotype correlation in X-linked Alport syndrome: impact on genetic counseling. Nephrol Dial Transpl 2002; 17: 1218-1227. (Pubitemid 34812066)
4. Alport AC. Hereditary familial congenital haemorrhagic nephritis. Br Med J 1927; 1: 504-506.
5. Gross O, Beirowski B, Koepke M-L et al. Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int 2003; 63: 438-446. (Pubitemid 36126790)
6. Gross O, Schulze-Lohoff E, Koepke M-L et al. Antifibrotic, nephroprotective potential of ACE-inhibitor vs AT1-antagonist in a murine model of progressive fibrosis. Nephrol Dial Transplant 2004; 19: 1716-1723. (Pubitemid 38961379)
7. Abbate M, Remuzzi G. Renoprotection: clues from knockout models of rare diseases. Kidney Int 2003; 63: 764-766. (Pubitemid 36126826)
8. Gross O, Kashtan C. Treatment of Alport syndrome: beyond animal models. Kidney Int 2009; 76: 599-603.
9. Hudson B, Tryggvason K, Sundaramoorthy M et al. Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med 2003; 348: 25.
10. Flinter FA, Cameron JS, Chantler C et al. Genetics of classic Alport's syndrome. Lancet 1988; ii: 1005-1007.
11. Jais JP, Knebelmann B, Giatras I et al. X-linked Alport syndrome: natural history in 195 families and genotype-phenotype correlations in males. J Am Soc Nephrol 2000; 11: 649-657. (Pubitemid 30171874)
12. Proesmans W, van Dyck M. Enalapril in children with Alport syndrome. Pediatr Nephrol 2004; 19: 271-275. (Pubitemid 38313009)
13. Ruggenenti P, Fassi A, Ilieva AP et al., Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951. (Pubitemid 39447135)
14. Ruggenenti P, Perna A, Remuzzi G, Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol 2001; 12: 2832-2837. (Pubitemid 33115432)
15. Remuzzi G, Ruggenenti P, Perna A et al., RENAAL Study Group. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J Am Soc Nephrol 2004; 15: 3117-3125. (Pubitemid 39578844)
16. Zannad F, Kesseler M, Lehert P et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006; 70: 1318-1324. (Pubitemid 44435184)
17. Wühl E, Trivelli A, Picca S et al., ESCAPE Trial Group, Strict blood-pressure control and progression of renal failure in children. N Engl J Med 2009; 361: 1639-1650.
18. Ingelfinger JR. Blood-pressure control and delay in progression of kidney disease in children. N Engl J Med 2009; 361: 1701-1703.
19. Klag MJ, Whelton PK, Randall BL et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13-18. (Pubitemid 26012498)
20. Ruggenenti P, Remuzzi G. Proteinuria: is the ONTARGET renal substudy actually off target? Nat Rev Nephrol 2009; 5: 436-437.
21. Ritz E, Viberti GC, Ruilope LM et al. Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetologia 2010; 53: 49-57.
22. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-1863.
23. Ruggenenti P, Cravedi P, Remuzzi G. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol 2010; 6: 319-330.
24. Cosgrove D, Rodgers K, Meehan D et al. Integrin alpa1beta1 and transforming growth factor-beta1 play distinct roles in Alport glomerular pathogenesis and serve as dual targets for metabolic therapy. Am J Pathol 2000; 157: 1649-1659.
25. Gross O, Girgert R, Beirowki B et al. Loss of collagen-receptor DDR1 preserves podocytes' architecture and delays renal fibrosis in genetic kidney disease. Matrix Biol 2010; 29: 346-356.
26. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047. (Pubitemid 350074801)
27. US Renal Data System. USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, 2008.
28. Szczech LA, Harmon W, Hostetter TH et al. World Kidney Day 2009: problems and challenges in the emerging epidemic of kidney disease. J Am Soc Nephrol 2009; 20: 453-464.
29. Bekheirnia MR, Reed B, Gregory MC et al. Genotype-phenotype correlation in X-linked Alport syndrome. J Am Soc Nephrol 2010; 21: 876-883.
30. Bland JM, Altman DG. Statistics note: the logrank test. BMJ 2004; 328: 1073.
31. Andersen PK, Borgan O, Gill RD et al. Statistical Models Based on Counting Processes, Section V.3.2, Springer Verlag: New York, 1993 pp 382-388.